Two new deals are announced in what is turning out to be an eventful week for SPACs. In today's dish, an oncology-focused drug developer who previously broke off a SPAC merger gets a rebound SPAC, and a psychedelic-focused biopharmaceutical company looks to make its experimental treatment mainstream. Read on to find out the latest about all things SPACs.
Source: SPAC Switcheroo